Letermovir

Letermovir (INN; trade name Prevymis) is an antiviral drug for the treatment of cytomegalovirus (CMV) infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections.[1] The drug was developed by Merck & Co., Inc as investigative compound MK-8228.[2]

Letermovir
Clinical data
Trade namesPrevymis
Other namesAIC246; MK-8228
AHFS/Drugs.comMonograph
MedlinePlusa618006
Routes of
administration
By mouth, intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.232.644
Chemical and physical data
FormulaC29H28F4N4O4
Molar mass572.561 g·mol−1
3D model (JSmol)

The drug was granted fast track status by the US Food and Drug Administration (FDA) and orphan drug status by the European Medicines Agency.[1] In the United States, it is approved for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant.[3]

References

  1. "Neues Virostatikum Letermovir" (in German). Deutsche Apothekerzeitung. 2011-08-29.
  2. Masangkay, Estel Grace (July 29, 2014). "Merck Kicks Off Phase 3 Study Of CMV Drug Letermovir". Retrieved 8 Oct 2014.
  3. "FDA Approves Letermovir for CMV Prophylaxis Post-Transplantation". onclive.com. November 9, 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.